
-
Lopetegui appointed coach of Qatar
-
UK counter-terrorism unit probes rappers Kneecap but music stars back band
-
Yamal heroics preserve Barca Champions League final dream
-
2026 T20 World Cup 'biggest women's cricket event in England' - ECB
-
Bangladesh begins three days of mass political rallies
-
Children learn emergency drills as Kashmir tensions rise
-
Millions of children to suffer from Trump aid cuts
-
Veteran Wallaby Beale set for long-awaited injury return
-
Syria's Druze take up arms to defend their town against Islamists
-
Tesla sales plunge further in France, down 59% in April
-
US calls on India and Pakistan to 'de-escalate'
-
Israel reopens key roads as firefighters battle blaze
-
Europe far-right surge masks divisions
-
James will mull NBA future after Lakers playoff exit
-
Ukraine's chief rabbi sings plea to Trump to side with Kyiv
-
Australian mushroom meal victim 'hunched' in pain, court hears
-
Lakers dumped out of playoffs by Wolves, Rockets rout Warriors
-
Booming tourism and climate change threaten Albania's coast
-
US reaching out to China for tariff talks: Beijing state media
-
Tariffs prompt Bank of Japan to lower growth forecasts
-
Kiss faces little time to set Wallabies on path to home World Cup glory
-
Serbian students, unions join forces for anti-corruption protest
-
Slow and easily beaten -- Messi's Miami project risks global embarrassment
-
Fan in hospital after falling to field at Pirates game
-
Nuclear power sparks Australian election battle
-
Tokyo stocks rise as BoJ holds rates steady
-
Bank of Japan holds rates, lowers growth forecasts
-
'Sleeping giants' Bordeaux-Begles awaken before Champions Cup semis
-
Napoli eye Scudetto as Inter hope for post-Barca bounce-back
-
Germany's 'absolutely insane' second tier rivalling Europe's best
-
PSG minds on Arsenal return as French clubs scrap for Champions League places
-
UK WWII veteran remembers joy of war's end, 80 years on
-
Myanmar junta lets post-quake truce expire
-
Rockets romp past Warriors to extend NBA playoff series
-
Messi, Inter Miami CONCACAF Cup dream over as Vancouver advance
-
UN body warns over Trump's deep-sea mining order
-
UK local elections test big two parties
-
US judge says Apple defied order in App Store case
-
Seventeen years later, Brood XIV cicadas emerge in US
-
Scorching 1,500m return for Olympic great Ledecky in Florida
-
Israel's Netanyahu warns wildfires could reach Jerusalem
-
Istanbul lockdown aims to prevent May Day marches
-
Budget Approval Expected Saturday for RONN Inc.-Saudi Arabia Hydrogen Joint Venture
-
May is Teen Mental Health Awareness Month Avel eCare Provides Crucial Support for Teens in Crisis-At Home and In School
-
Interactive Strength Inc. (Nasdaq:TRNR) Updates Shareholders on 2025 Progress To Date
-
NextSource Materials Announces Executive Transition to Drive Molo Mine Optimization and Prepare for Future Expansion
-
Trademark Renovations Named 2025 Consumer Choice Award Winner for Home Renovation in Southern Alberta
-
NURAN WIRELESS Reports Annual Audited 2024 Financial Results
-
Organto Foods Announces Debentureholder Approval of Settlement Terms
-
Mereo Networks Acquires DISH Fiber and Rebrands as Mereo Fiber

US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
L.Durand--AMWN